Skip to Content

Are you based in North America? If yes, switch to our North American website →

ZNF217 Amplification

Catalogue Numbers
LPS 005-S (5 tests)
LPS 005 (10 tests)

Probe Specification

  • ZNF217, 20q13.2, Red
  • 20pter, 20p13, Green

The ZNF217 Amplification probe consists of a 197kb red probe spanning the ZNF217 gene and neighbouring regions. The accompanying 20pter probe in green acts as a control for chromosome 20.

Probe Information

The Zinc Finger protein 217 gene (ZNF217), which functions as a transcription repressor for a variety of genes1, is a strong oncogene candidate mapped within the 260kb minimum common amplicon at 20q13.22.

ZNF217 is amplified in breast cancer2,3, ovarian cancer and other tumours3,4,5 and is associated with aggressive tumour behaviour6. It has been shown that the silencing of ZNF217 inhibits ovarian cancer cell growth and their invasive ability in cancer cell lines7.

It was very important for us to have more consistent results with our probes — easy-to-read bright signals and a range of vial sizes, which is much more cost-effective. It also was critical to upgrade our pretreatment kit to expedite the analysis of FFPE samples. We can now complete the process in about 90 minutes. Janet M. Cowan, PhD, Director of the Cytogenetics Laboratory at Tufts Medical Center


1. Quinlan KG et al., Mol Cell Biol 2006;26:8159-72

2. Collins C et al., Proc Natl Acad Sci 1998;95:8703-8

3. Yang SH et al., Clin Cancer Res 2005;11:612-20

4. Iwabuchi H et al., Cancer Res 1995;55:6172-80

5. Bar-Shira A et al., Cancer Res 2002;62:6803-7

6. Tanner MM et al., Clin Canc Res 1995;1:1455-61

7. Sun G et al., Int J Oncol 2008;32:1065-71

Microscope Images

ZNF217 Amplification magnified
Area of Interest*
Breast Cancer, Ovarian Cancer, Sarcoma, Prostate Cancer


This product is intended to be used on formalin-fixed paraffin-embedded (FFPE) tissues.

*Disease information supported by the literature and is not a reflection of the intended purpose of this product.